Tei index in adult patients submitted to adriamycin chemotherapy: failure to predict early systolic dysfunction

Rohde, Luís Eduardo Paim; Baldi, Alexandre; Weber, Cristiane Seganfredo; Geib, Guilherme; Mazzotti, Nicolle Gollo; Fiorentini, Marlon Roberto; Roggia, Murilo Felix; Pereira, Rodrigo dos Santos; Clausell, Nadine Oliveira

doi:10.1007/s10554-006-9145-0

Cited by 13 publications

(9 citation statements)

References 23 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…146,147 The prognostic value of myocardial performance index could not be replicated in subsequent studies. 148 Two studies have reported LV diastolic abnormalities late after anthracycline administration; these abnormalities were associated with wall motion abnormalities despite a preserved LVEF. 149 Another study reported that a reduced transmitral E/A ratio was associated with a reduction in longitudinal strain by STE in patients with normal LVEFs late after treatment.…”

Section: Diastolic Dysfunction: Early Signs and Prognostic Valuementioning

confidence: 99%

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Plana

Galderisi

Barac

et al. 2014

Journal of the American Society of Echocardiography

1,282

1,209

View full text Add to dashboard Cite

Section: Diastolic Dysfunction: Early Signs and Prognostic Valuementioning

confidence: 99%

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Plana

Galderisi

Barac

et al. 2014

Journal of the American Society of Echocardiography

1,282

1,209

View full text Add to dashboard Cite

“…Our search yielded 212 potentially relevant studies. After a detailed review of titles, abstracts, and subsequently full articles for potentially relevant studies, 13 studies (1,14,15,16,17,18,19,20,21,22,23,24,30) were identified and included in the final review (Fig. 3).…”

Section: Resultsmentioning

confidence: 99%

The role of the Tei index in assessing for cardiotoxicity from anthracycline chemotherapy: a systematic review

et al. 2021

View full text Add to dashboard Cite

Background: Anthracycline agents are known to be effective treatments for solid tumors and hematological malignancies. Although these agents improve survival, their use is associated with cardiotoxic effects, which most commonly manifests as left ventricular systolic dysfunction (LVSD). As such guidelines recommend the periodic assessment of left ventricular ejection fraction (LVEF). However, as diastolic dysfunction likely proceeds systolic impairment in this setting, the role of Tei index may offer additional benefit in detecting subclinical LVSD. Methods: We conducted a systematic review to investigate the evidence for the use of Tei index in assessing for subclinical cardiotoxicity in patients receiving anticancer agents. A search of Medline and EMBASE was performed and relevant studies were reviewed and narratively synthesized. Results: A total of 13 studies were included with a total of 800 patients (mean age range 46-62 years, percentage of male participants ranged from 0%-86.9%). An increase in Tei index was observed in 11 studies, which suggesting a decline in cardiac function following chemotherapy. Out of these, 6 studies indicated that the Tei index is a useful parameter in predicting cardiotoxic LVSD. Furthermore, 5 studies indicated Tei index to be superior to LVEF in detecting subclinical cardiotoxicity. Conclusions: While there are some studies that suggest that Tei index may be a useful indicator in assessing for subclinical anthracycline related cardiotoxicity, the findings are inconsistent so more studies are needed before the evaluation of Tei index should be performed routinely in patients receiving chemotherapy.

show abstract

“…According to the findings summarized in tables, it can be judged that myocardial damage in these patients are subclinical which is shown in MPI, and because of its progressive nature later engaged to involvement of EF and FS parameters. This process is justified through compensatory mechanisms that occur in the heart muscle (10, 19). In our study, tissue doppler showed a decreasing of IVRT in right and left ventricles in both groups, which is indicating improvement of left and right ventricular diastolic function after treatment.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Coenzyme Q10 on echocardiographic parameters of patients with Duchenne muscular dystrophy

Salehi¹,

Zeinaloo²,

Riasi³

et al. 2017

Electron physician

View full text Add to dashboard Cite

BackgroundMyocardial damage is a common complication in patients with Duchenne muscular dystrophy (DMD) that occurs due to myocardial replacement by fat and fibrosis. In recent years, efforts have been made toward finding new pharmacological agents with fewer complications which can be used as prophylactic before the symptoms. Coenzyme Q10 plays a central role in production of bioenergy in heart muscle and antioxidant in reperfusion condition of myocardial damaged muscle and leads to membrane stability and prevents cell death.ObjectiveThis study aimed at comparing the Effectiveness of coenzyme Q10 on echocardiographic parameters of pediatric patients with Duchenne muscular dystrophy.MethodsThis randomized clinical trial study (RCT) was carried out on 25 pediatric patients with pre-diagnosed DMD who attended the Children’s Medical Center (CMC), Tehran, Iran from February 2013 to 2015. The patients were randomly divided into two groups. Group-1; (n=12) was treated with coenzyme Q10 for six months and group-2 ;(n=13) received placebo for the same time. The primary aim was to compare the myocardial performance index (MPI), between the two groups at the end of six months. Data were analyzed by SPSS software (ver-16) and using T-Test.ResultsTwenty-five patients under study were divided into two groups of (Q10=12) and (placebo=13). Mean ages were 8.9±1.7 and 8.6±1.4 in Q10 and placebo groups (P=0.66). No significant difference was detected in MPI at all three views of mitral and tricuspid and septum respectively in two groups after the end of treatment (0.41±0.13, and 0.43±0.6; P=0.59), (0.45±0.12, and 0.46±0.1; P=0.05), and (0.45±0.06, and 0.45±0.1; P=0.31).ConclusionAccording to the results obtained from this study, coenzyme Q10 had no significant effect on improving the performance of echocardiographic parameters in patients with DMD.Trial registrationThe trial is registered at the Iranian Clinical Trial Registry (IRCT.ir) with the IRCT identification number IRCT2015070223018N1.FundingThis research has been financially supported by the Research Council of Tehran University of Medical Sciences.

show abstract

Tei index in adult patients submitted to adriamycin chemotherapy: failure to predict early systolic dysfunction

Abstract: Tei index does not appear to be a useful tool for detection of early adriamycin cardiotoxicity in adults.

Cited by 13 publications

References 23 publications

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

The role of the Tei index in assessing for cardiotoxicity from anthracycline chemotherapy: a systematic review

Effectiveness of Coenzyme Q10 on echocardiographic parameters of patients with Duchenne muscular dystrophy

Contact Info

Product

Resources

About